Cirrus Pharmaceuticals, a contract developer of drug formulations, has been acquired by India-based Kemwell Biopharma, which is aiming to broaden its own contract offerings.
Cirrus has drug development expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms. The Research Triangle Park company was founded in 1997. Kemwell focuses on developing and manufacturing drugs for pharmaceutical companies. The Bangalore-based company bills itself as one of the largest contract drug development/manufacturing organizations in India.
No financial terms for the Cirrus acquisition were disclosed.
Kemwell Chairman Anurag Bagaria said in a statement that the company’s corporate objective is to build a global contract services company. Cirrus brings early development services in the United States to complement Kemwell’s commercial manufacturing in facilities in India and Sweden.
Kemwell say that its client list includes Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis and Pfizer. The company employs more than 1,200 employees wordwide and seven production facilities and R&D laboratories in India and Sweden.